Exelixis Will Have 15 Presentations at the 2008 EORTC-NCI-AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 16, 2008 - Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that this information is also available on the EORTC website. -0-
WEDNESDAY, October 22 ---------------------------------------------------------------------- Location: Poster Hall Time: 12 noon-2:15 pm Topic: Biomarkers (PP57) Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway Poster #89 Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647 Poster #97 Topic: Heat shock proteins (PP26) XL888, a novel, synthetic, orally bioavailable inhibitor of HSP90 Poster #144 Topic: Phase 2 (PP44) A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib Poster #212 Topic: PI3Kinase (PP45) A phase 1 dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors Poster #216 A phase 1 dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors Poster #218 THURSDAY, October 23 ---------------------------------------------------------------------- Location: Poster Hall Time: 12 noon-3:00 pm Topic: New Molecular Targets (PP35) Identification of XL413, a selective Cdc7 kinase inhibitor which induces cell cycle arrest and exhibits potent antitumor activity Poster #339 Identification of potent, selective sphingosine-1-phosphate 1 receptor (S1P1R) antagonists with antitumor activity Poster #335 Topic: Phase 1 (PP43) A phase 1 study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) Poster #379 A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients with advanced solid tumors Poster #383 A phase 1 dose-escalation study of XL228, a potent IGF1R / Src inhibitor, in patients with advanced malignancies Poster #390 Phase 1 study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies Poster #395 Topic: mTOR (PP33) mTORC1/mTORC2 selective inhibitors: Identification and characterization of novel small molecules with anti-tumor activity Poster #322 Topic: Cyclins and CDK's (PP14) Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis Poster #291 FRIDAY, October 24 ---------------------------------------------------------------------- Location: Poster Hall Time: 12 noon-2:00 pm Topic: Signal Transduction Modulators (PP38) Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design Poster #552
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Contact
Exelixis, Inc.
Charles Butler, 650-837-7277
Senior Director
Corporate Communications
& Investor Relations
cbutler@exelixis.com
Soleil Harrison, 650-837-7012
Senior Manager
Corporate Communications
sharrison@exelixis.com
Posted: October 2008
